HSBC Maintains Reduce on bluebird bio, Lowers Price Target to $1.02
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt maintains a Reduce rating on bluebird bio (NASDAQ:BLUE) and lowers the price target from $2.31 to $1.02.
March 05, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HSBC maintains a Reduce rating on bluebird bio and lowers the price target from $2.31 to $1.02.
The reduction in price target by HSBC, a major financial institution, suggests a bearish outlook on bluebird bio's stock. This could lead to a decrease in investor confidence and potentially lower the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100